{
    "root": "3000f004-710e-edc2-e063-6294a90a86ce",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Escitalopram",
    "value": "20250310",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ESCITALOPRAM OXALATE",
            "code": "5U85DBW7LO"
        }
    ],
    "indications": "Escitalopram is indicated for the treatment of:\n                  \n                     major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older.\n                     generalized anxiety disorder (GAD) in adults.\n                  \n                  \n                     Additional pediatric use information is approved for AbbVie Inc.’s LEXAPRO (escitalopram) tablets and LEXAPRO (escitalopram) oral solution. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.",
    "contraindications": "Indication and Population Recommended Dosage MDD in Adults ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older ( 2.1 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults ( 2.2 ) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits were seen at 20 mg once daily ( 2.1 ) Administer once daily, morning or evening, with or without food ( 2.3 ) Elderly patients: recommended dosage is 10 mg once daily ( 2.4 ) Hepatic impairment: recommended dosage is 10 mg once daily ( 2.4 , 8.6 ) When discontinuing escitalopram tablets, reduce dose gradually whenever possible ( 2.5 )",
    "warningsAndPrecautions": "Escitalopram Tablets, USP,20 mg are round, white to off-white, biconvex, film coated tablets, debossed with \"P 20\" on the scored side and plain on the other side. They are supplied in\n                  NDC: 70518-2317-00\n                  NDC: 70518-2317-01\n                  NDC: 70518-2317-02\n                  NDC: 70518-2317-03\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Escitalopram tablets are contraindicated in patients:\n                  \n                     taking MAOIs with escitalopram tablets or within 14 days of stopping treatment with escitalopram tablets because of an increased risk of serotonin syndrome. The use of escitalopram tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated\n  \n   [see Dosage and Administration (\n   \n    2.7) and Warnings and Precautions (\n   \n    5.2)]\n  \n   . Starting escitalopram tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome\n  \n   [see Dosage and Administration (\n   \n    2.6) and Warnings and Precautions (\n   \n    5.2)]\n  \n   .\n \n  \n                     taking pimozide\n  \n   [see Drug Interactions (\n   \n    7)]\n  \n   .\n \n  \n                     with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in escitalopram tablets."
}